The quarter included three IPOs worth US$ 428 million and one Qualified Institutional Placement (QIP) worth US$ 88 million
Max and Luna personify HRV Pharma’s core values of trust, loyalty, and authentic partnership
It represents a 30% increase in the company’s production capacity and introduces a segment dedicated to highly potent active ingredients
With global certification in place, the Ambernath site expands Supriya’s footprint beyond APIs into high-margin formulations
Ultra-high purity surfactant for biologics and parenteral drug formulations
The inspection concluded with zero form 483 observations
Brenntag Specialties will provide pharmaceutical manufacturers and biopharmaceutical companies with a reliable supply of high-purity, GMP-compliant acetates
Subscribe To Our Newsletter & Stay Updated